Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 18 — Focus on rare liver diseases, with Albireo CEO Ron Cooper

Pharmaceutical
Simon Wentworth
31 October 2022
episode18-big

More on this story...

Biotechnology
Albireo shares rocket as study sets up second Bylvay approval
12 October 2022
Biotechnology
NICE backs NHS use of Albireo's Bylvay for all PFIC types
22 February 2022
Biotechnology
Albireo's Bylvay gets FDA green light for PFIC
21 July 2021
Pharmaceutical
Evaluate expects Roche to lead the way in steady pharma growth to 2028
21 October 2022


Companies featured in this story

More ones to watch >


Today's issue

Nektar sells its PEGylation reagent manufacturing business
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Pharmaceutical

PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Photocure’s Hexvix wins Chinese approval
5 November 2024
Vertex ups guidance again as results exceed estimates
5 November 2024
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze